FORM 4
--------

Ľ

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. *See* Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION OMB APPROVAL Washington, D.C. 20549 OMB 323

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL OMB 3235-Number: 0287 Estimated average burden hours per response... 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)												
1. Name and Address MARIO ERNEST	2. Issuer Name <b>and</b> Ticker or Trading Symbol Tonix Pharmaceuticals Holding Corp. [TNXP]						5. Relationship of Reporting Person(s) to Issuer (Check all applicable) 0fficer (give title 0fther (specify below)					
(Last) (1 C/O TONIX PHA HOLDING CORF AVENUE, SUITE		3. Date of Earliest Transaction (Month/Day/Year) 09/29/2014						below)				
	(Street) NEW YORK, NY 10022				e Ori	ginal			6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting Person			
(City) (S	(City) (State) (Zip)				ivati	ive Secur	red, Disposed of, or I	Beneficially (	Owned			
(Instr. 3) Date Exec (Month/Day/Year) any		Deemed ution Date, if nth/Day/Year)	Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) (Amount (D) Pr		D)	Following Reported Transaction(s) (Instr. 3 and 4)	Direct (D)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
Common Stock, \$0.001 par value	09/29/2014			Х		10,000	A	\$ 4.25	136,472	D		

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of SEC 1474 information contained in this form are not (9-02) required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

	( <i>e.g.</i> , puts, calls, warrants, options, convertible securities)														
1. Title of Derivative	2. Conversion		3A. Deemed Execution Date, if					7. Title and Amount of			9. Number of Derivative	10. Ownership	11. Nature of Indirect		
Security	or Exercise	(Month/Day/Year)	any	Code			(Month/Day/Year) U		Underlying		Security	Securities	Form of	Beneficial	
(Instr. 3)	Price of		(Month/Day/Year)	(Instr. 8	)	Secu	urities		· · · · · · · · · · · · · · · · · · ·		(Instr. 5)	Beneficially	Derivative	Ownership	
	Derivative					-	uired	(		(Instr. 3 and 4)				Security:	(Instr. 4)
	Security					(A)					0	Direct (D)			
						-	oosed of					Reported Transaction(s)	or Indirect		
						(D) (Inst	tr. 3, 4,					(1) (Instr. 4)			
							and 5)					(msu. i)	(Insu: I)		
							,				Amount				
								Date Exercisable	Expiration Date	Title	or Number				
				Code	v	(A)	(D)				of Shares				
Series A common stock purchase warrant	\$ 4.25	09/29/2014		х			10,000	08/14/2013	08/14/2018	common stock	10,000	\$0	30,000	D	

## **Reporting Owners**

Baractica Orman Nama (Address	Relationships						
Reporting Owner Name / Address	Director	10% Owner	Officer	Other			
MARIO ERNEST C/O TONIX PHARMACEUTICALS HOLDING CORP. 509 MADISON AVENUE, SUITE 306 NEW YORK, NY 10022	Х						

## Signatures

/s/Jessica Edgar, Attorney-in-Fact	09/29/2014
**Signature of Reporting Person	Date

## **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.